within Pharmacolibrary.Drugs.ATC.B;

model B06AC03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.166666666666665e-07,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00013000000000000002,
    k12             = 0.035,
    k21             = 0.035
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B06AC03</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ecallantide is a recombinant protein and a selective inhibitor of plasma kallikrein, used primarily for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is administered subcutaneously and is approved for use in several countries including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are described for healthy adult volunteers and patients with hereditary angioedema after single subcutaneous administration.</p><h4>References</h4><ol><li><p>Bernstein, JA, &amp; Qazi, M (2010). Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. <i>Expert review of clinical immunology</i> 6(1) 29–39. DOI:<a href=\"https://doi.org/10.1586/eci.09.60\">10.1586/eci.09.60</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20383888/\">https://pubmed.ncbi.nlm.nih.gov/20383888</a></p></li><li><p>Martello, JL, et al., &amp; Chambers, H (2012). Ecallantide for treatment of acute attacks of hereditary angioedema. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 69(8) 651–657. DOI:<a href=\"https://doi.org/10.2146/ajhp110227\">10.2146/ajhp110227</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22472866/\">https://pubmed.ncbi.nlm.nih.gov/22472866</a></p></li><li><p>Garnock-Jones, KP (2010). Ecallantide: in acute hereditary angioedema. <i>Drugs</i> 70(11) 1423–1431. DOI:<a href=\"https://doi.org/10.2165/11205850-000000000-00000\">10.2165/11205850-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20614949/\">https://pubmed.ncbi.nlm.nih.gov/20614949</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B06AC03;
